sglt2 inhibitor glp 1 agonist combination Full article: and GLP-1 receptor therapy: a complementary approach to the treatment of type 2 diabetes GLP-1 Receptor Agonists and SGLT2

In general, gastrointestinal side effects, especially constipation, may persist even as other symptoms diminish over time and appear to occur less frequently with long-acting GLP-1 RAs [118]

Initially developed for type 2 diabetes management, GLP-1 agonists effectively promote weight loss in preclinical and clinical studies [11] [12], leading to their investigation and subsequent approval for obesity treatment in non-diabetic patients

Henry Meds at $297/mo is competitive, but its pharmacy partner carries a federal plea agreement

95% CI 1.6, 0.39), phentermine/topiramate (WMD: 0.7

Side effect comparison All three compounds share a similar gastrointestinal side effect profile, which is expected given that all three activate the GLP-1 receptor

Implications for employers: - Rebates and discounts are large for GLP-1 drugs for diabetes and obesity, and employers need to consider this when planning management programs and building future pharmacy budgets